NEW YORK, NY / ACCESSWIRE / July 10, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) is a biopharmaceutical company that develops targeted therapeutics for oncology and other areas of unmet medical need. The company's proprietary platform has delivered various insights into cancer and other related diseases. AVEO's primary product candidate is tivozanib, which is being developed as a treatment for renal cell carcinoma (RCC).
Tivozanib is the company's most advanced product candidate. Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). The drug is designed to inhibit the VEGF pathway, which is critical for cancer angiogenesis (the formation of new blood vessels essential for cell proliferation, migration, and survival). Tivozanib has been investigated for use with renal cell, colorectal, and breast cancers.
Our full report discusses tivozanib and reviews potential upcoming milestones READ MORE.
Copy and paste to your browser may be required to view the report – http://tradersnewssource.com/aveo/
In December 2015, the company entered into a license agreement with EUSA Pharma (UK) Limited that grants EUSA the right to develop and commercialize tivozanib in Europe, Latin America, Africa, Australasia, and New Zealand. Tivozanib is currently under consideration for marketing approval in the European Union.
With respect to the United States, the company is preparing a Phase III trial (TIVO-3) and expects to report initial data in the first quarter of 2018. The company has also initiated a Phase I/II clinical trial (TiNivo) of tivozanib in combination with nivolumab, an immune checkpoint inhibitor, for the treatment of RCC.
Tivozanib appears to be a promising candidate for the treatment for the treatment of RCC and potentially other forms of cancer as well. However, AVEO must complete its TIVO-3 Phase III trial, which is expected to read out in the first quarter of 2018.
Get details on the AVEO pipeline and a Q1 financial review READ MORE.
Copy and paste to your browser may be required to view the report - http://tradersnewssource.com/aveo/
DISCLOSURE
Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
TNS has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. Ivan Neilson, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
CONTACT:
SOURCE: Traders News Source
ReleaseID: 467671
